1. Home
  2. IGC
  3. IGC News

Latest IGC Pharma Inc. (IGC) News on November 25, 2025

IGC Pharma Inc (IGC) Q2 2026 Earnings Call Highlights: Strategic Advances and Financial Maneuvers
IGC

GuruFocus.com

8 days ago

IGC Pharma Inc (IGC) Q2 2026 Earnings Call Highlights: Strategic Advances and Financial Maneuvers

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
IGC

ACCESS Newswire

8 days ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates
IGC

Zacks

11 days ago

IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates

Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates
IGC

Zacks

12 days ago

Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders
IGC

ACCESS Newswire

12 days ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
IGC

Zacks

13 days ago

Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates

Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates
IGC

Zacks

15 days ago

Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
IGC

ACCESS Newswire

15 days ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
IGC

Zacks

19 days ago

Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline
IGC

ACCESS Newswire

22 days ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy
IGC

Zacks

a month ago

All You Need to Know About IGC Pharma, Inc. (IGC) Rating Upgrade to Strong Buy

Best Momentum Stocks to Buy for Oct. 24
IGC

Zacks

a month ago

Best Momentum Stocks to Buy for Oct. 24

New Strong Buy Stocks for Oct. 24: IGC, ASM and More
IGC

Zacks

a month ago

New Strong Buy Stocks for Oct. 24: IGC, ASM and More

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"
IGC

ACCESS Newswire

a month ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences
IGC

ACCESS Newswire

a month ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

IGC

ACCESS Newswire

a month ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease
IGC

ACCESS Newswire

2 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

IGC

ACCESS Newswire

5 months ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates
IGC

Zacks

5 months ago

IGC Pharma, Inc. (IGC) Reports Q4 Loss, Beats Revenue Estimates

IGC

ACCESS Newswire

5 months ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

IGC

ACCESS Newswire

5 months ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

IGC

ACCESS Newswire

6 months ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

IGC

ACCESS Newswire

6 months ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

IGC Pharma Welcomes Strategic Investment from Advisors
IGC

ACCESS Newswire

7 months ago

IGC Pharma Welcomes Strategic Investment from Advisors

IGC

ACCESS Newswire

7 months ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

IGC Pharma expands CALMA trial with addition of Butler Hospital Program
IGC

TipRanks

8 months ago

IGC Pharma expands CALMA trial with addition of Butler Hospital Program

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program
IGC

ACCESS Newswire

8 months ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health
IGC

ACCESS Newswire

8 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances
IGC

ACCESS Newswire

8 months ago

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences
IGC

ACCESS Newswire

8 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

IGC

ACCESS Newswire

8 months ago

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

IGC

ACCESS Newswire

8 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock. Raising P/T to $4.25"

IGC

ACCESS Newswire

9 months ago

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection
IGC

ACCESS Newswire

9 months ago

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

IGC Pharma expands Holiby line with ‘Longevity’, ‘Renew’
IGC

TipRanks

9 months ago

IGC Pharma expands Holiby line with ‘Longevity’, ‘Renew’

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
IGC

ACCESS Newswire

9 months ago

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

IGC

ACCESS Newswire

9 months ago

IGC Pharma Reports Third Quarter Fiscal 2025 Results

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)
IGC

ACCESS Newswire

9 months ago

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease
IGC

ACCESS Newswire

10 months ago

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor
IGC

ACCESS Newswire

10 months ago

IGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic Advisor

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
IGC

ACCESS Newswire

10 months ago

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

IGC

ACCESSWIRE

a year ago

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

IGC

ACCESSWIRE

a year ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

IGC

ACCESSWIRE

a year ago

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment
IGC

Business Wire

a year ago

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
IGC

ACCESSWIRE

a year ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline

IGC

ACCESSWIRE

a year ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies

IGC

ACCESSWIRE

a year ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
IGC

ACCESSWIRE

a year ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
IGC

Business Wire

a year ago

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease
IGC

Business Wire

a year ago

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Announces Results of its 2024 Annual Stockholders Meeting
IGC

Business Wire

a year ago

IGC Announces Results of its 2024 Annual Stockholders Meeting

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease
IGC

Business Wire

a year ago

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
IGC

Business Wire

a year ago

IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist

IGC Pharma Reports First Quarter Fiscal 2025 Results
IGC

Business Wire

a year ago

IGC Pharma Reports First Quarter Fiscal 2025 Results

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target
IGC

Business Wire

a year ago

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
IGC

Business Wire

a year ago

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
IGC

Business Wire

a year ago

IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease

IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
IGC

Business Wire

a year ago

IGC Reports Financial Results for Fiscal Year Ended March 31, 2024

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
IGC

Business Wire

a year ago

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol
IGC

Business Wire

a year ago

IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta 9 Tetrahydrocannabinol

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
IGC

Business Wire

a year ago

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

IGC Pharma to Attend BIO International Convention 2024
IGC

Business Wire

2 years ago

IGC Pharma to Attend BIO International Convention 2024

IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
IGC

Business Wire

2 years ago

IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two

IGC Pharma Adds Advisor in Artificial Intelligence
IGC

Business Wire

2 years ago

IGC Pharma Adds Advisor in Artificial Intelligence

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
IGC

Business Wire

2 years ago

IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
IGC

Business Wire

2 years ago

IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
IGC

Business Wire

2 years ago

IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
IGC

Business Wire

2 years ago

IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
IGC

Business Wire

2 years ago

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a "Buy" Recommendation and $3.00 Price Target
IGC

Business Wire

2 years ago

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a "Buy" Recommendation and $3.00 Price Target

IGC Pharma Reports Third Quarter Fiscal 2024 Results
IGC

Business Wire

2 years ago

IGC Pharma Reports Third Quarter Fiscal 2024 Results

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
IGC

Business Wire

2 years ago

IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model

Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer
IGC

GlobeNewswire

2 years ago

Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer

IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
IGC

Business Wire

2 years ago

IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s

SPAR Group (NASDAQ:SGRP) Is Very Good At Capital Allocation
IGC

Simply Wall St.

2 years ago

SPAR Group (NASDAQ:SGRP) Is Very Good At Capital Allocation

Jewelry Looking Grimy? Here’s How to Clean It at Home
IGC

The Wall Street Journal

2 years ago

Jewelry Looking Grimy? Here’s How to Clean It at Home

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial
IGC

Business Wire

2 years ago

IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial

Contrarian Kings: 3 Unloved Stocks That Could Be the Next Market Darlings
IGC

InvestorPlace

2 years ago

Contrarian Kings: 3 Unloved Stocks That Could Be the Next Market Darlings

IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation
IGC

PR Newswire

2 years ago

IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation

Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding
IGC

GuruFocus.com

2 years ago

Seth Klarman's Firm Exits Atara Biotherapeutics Inc Holding

Pathward Financial, Inc. to Announce First Quarter 2024 Earnings and Host Conference Call on January 24, 2024
IGC

Business Wire

2 years ago

Pathward Financial, Inc. to Announce First Quarter 2024 Earnings and Host Conference Call on January 24, 2024

Alarum Estimates Record Revenue and All Time High Operating Cashflow for the Fourth Quarter of 2023
IGC

GlobeNewswire

2 years ago

Alarum Estimates Record Revenue and All Time High Operating Cashflow for the Fourth Quarter of 2023

CardRatings Unveils Its ‘Best Credit Cards of 2024’ List and Annual Cardholder Survey Results
IGC

Business Wire

2 years ago

CardRatings Unveils Its ‘Best Credit Cards of 2024’ List and Annual Cardholder Survey Results

American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event
IGC

Business Wire

2 years ago

American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event

American Medical Association (AMA) Grants Cardio Diagnostics Holdings, Inc.’s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, a Dedicated CPT PLA Reimbursement Code
IGC

Business Wire

2 years ago

American Medical Association (AMA) Grants Cardio Diagnostics Holdings, Inc.’s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, a Dedicated CPT PLA Reimbursement Code

Milestone Pharma (MIST) Down on Regulatory Update for Etripamil
IGC

Zacks

2 years ago

Milestone Pharma (MIST) Down on Regulatory Update for Etripamil

MicroAlgo Inc. Developed QSDLT to Provide a More Secure Foundation for Bitcoin and Other Cryptocurrency Systems
IGC

PR Newswire

2 years ago

MicroAlgo Inc. Developed QSDLT to Provide a More Secure Foundation for Bitcoin and Other Cryptocurrency Systems

Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
IGC

GlobeNewswire

2 years ago

Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.

Parke Bancorp (NASDAQ:PKBK) Has Announced A Dividend Of $0.18
IGC

Simply Wall St.

2 years ago

Parke Bancorp (NASDAQ:PKBK) Has Announced A Dividend Of $0.18

Ark Restaurants Corp. (NASDAQ:ARKR) Q4 2023 Earnings Call Transcript
IGC

Insider Monkey

2 years ago

Ark Restaurants Corp. (NASDAQ:ARKR) Q4 2023 Earnings Call Transcript

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s
IGC

Business Wire

2 years ago

Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s

Finance of America Receives Continued Listing Standard Notice from the NYSE
IGC

Business Wire

2 years ago

Finance of America Receives Continued Listing Standard Notice from the NYSE

Positive Signs As Multiple Insiders Buy Chimerix Stock
IGC

Simply Wall St.

2 years ago

Positive Signs As Multiple Insiders Buy Chimerix Stock

IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024
IGC

Business Wire

2 years ago

IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024

Navitas “Electrify Our World™” at CES 2024
IGC

GlobeNewswire

2 years ago

Navitas “Electrify Our World™” at CES 2024

IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
IGC

Business Wire

2 years ago

IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials

Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
IGC

GlobeNewswire

2 years ago

Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND

ClearSign Technologies (NASDAQ:CLIR) delivers shareholders notable 98% return over 1 year, surging 59% in the last week alone
IGC

Simply Wall St.

2 years ago

ClearSign Technologies (NASDAQ:CLIR) delivers shareholders notable 98% return over 1 year, surging 59% in the last week alone

IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives
IGC

Business Wire

2 years ago

IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives

Share on Social Networks: